Item 9 Labs Corp
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies thr… Read more
Item 9 Labs Corp (INLB) - Net Assets
Latest net assets as of June 2023: $52.64 Million USD
Based on the latest financial reports, Item 9 Labs Corp (INLB) has net assets worth $52.64 Million USD as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($112.02 Million) and total liabilities ($59.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $52.64 Million |
| % of Total Assets | 47.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | 2266.39% |
| 10-Year Change | N/A |
| Growth Volatility | 406.21 |
Item 9 Labs Corp - Net Assets Trend (2010–2022)
This chart illustrates how Item 9 Labs Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Item 9 Labs Corp (2010–2022)
The table below shows the annual net assets of Item 9 Labs Corp from 2010 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-09-30 | $61.94 Million | -28.06% |
| 2021-09-30 | $86.10 Million | +974.22% |
| 2020-09-30 | $8.02 Million | +9.25% |
| 2019-09-30 | $7.34 Million | +180.28% |
| 2018-09-30 | $2.62 Million | +217.37% |
| 2017-09-30 | $-2.23 Million | -7.57% |
| 2016-09-30 | $-2.07 Million | +58.41% |
| 2015-09-30 | $-4.98 Million | -89.08% |
| 2014-09-30 | $-2.64 Million | +10.26% |
| 2013-09-30 | $-2.94 Million | -28.57% |
| 2012-09-30 | $-2.29 Million | -4546.67% |
| 2011-09-30 | $-49.17K | -115.57% |
| 2010-09-30 | $-22.81K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Item 9 Labs Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6499358600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.99K | 0.02% |
| Other Components | $126.97 Million | 204.91% |
| Total Equity | $61.96 Million | 100.00% |
Item 9 Labs Corp Competitors by Market Cap
The table below lists competitors of Item 9 Labs Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HIGHLIGHT COMMUNICA (HLG.SG)
STU:HLG
|
$10.08K |
|
ZJLD Group Inc.
F:LH6
|
$10.08K |
|
Mercuries F&B Co., Ltd.
TW:7705
|
$10.08K |
|
Troilus Mining Corp
F:CM5
|
$10.09K |
|
Derimod Konfeksiyon Ayakkabi Deri Sanayi ve Ticaret AS
IS:DERIM
|
$10.08K |
|
REALTECH - Dusseldorf Stock Exchang
DU:RTC
|
$10.07K |
|
SPORTING
MU:SCG
|
$10.06K |
|
MAENDELEO BANK PLC
DSE:MBP
|
$10.06K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Item 9 Labs Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 86,101,443 to 61,961,411, a change of -24,140,032 (-28.0%).
- Net loss of 31,142,604 reduced equity.
- New share issuances of 657,815 increased equity.
- Other factors increased equity by 6,344,757.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-31.14 Million | -50.26% |
| Share Issuances | $657.82K | +1.06% |
| Other Changes | $6.34 Million | +10.24% |
| Total Change | $- | -28.04% |
Book Value vs Market Value Analysis
This analysis compares Item 9 Labs Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-09-30 | $-0.05 | $0.00 | x |
| 2011-09-30 | $-0.11 | $0.00 | x |
| 2012-09-30 | $-1.82 | $0.00 | x |
| 2013-09-30 | $-1.71 | $0.00 | x |
| 2014-09-30 | $-1.06 | $0.00 | x |
| 2015-09-30 | $-1.50 | $0.00 | x |
| 2016-09-30 | $-0.54 | $0.00 | x |
| 2017-09-30 | $-0.30 | $0.00 | x |
| 2018-09-30 | $0.96 | $0.00 | x |
| 2019-09-30 | $0.12 | $0.00 | x |
| 2020-09-30 | $0.13 | $0.00 | x |
| 2021-09-30 | $1.10 | $0.00 | x |
| 2022-09-30 | $0.65 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Item 9 Labs Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -50.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -143.14%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.79x
- Recent ROE (-50.26%) is below the historical average (-29.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.83K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.19K |
| 2012 | 0.00% | -458.17% | 0.78x | 0.00x | $-3.86 Million |
| 2013 | 0.00% | -972.27% | 0.77x | 0.00x | $-3.03 Million |
| 2014 | 0.00% | -9516.88% | 0.35x | 0.00x | $-16.82 Million |
| 2015 | 0.00% | -4194.48% | 1.00x | 0.00x | $-4.24 Million |
| 2016 | 0.00% | -964.59% | 3.63x | 0.00x | $-2.92 Million |
| 2017 | 0.00% | -109.28% | 2.25x | 0.00x | $-43.56K |
| 2018 | -24.54% | -46.70% | 0.39x | 1.34x | $-904.03K |
| 2019 | -142.50% | -215.47% | 0.34x | 1.94x | $-11.38 Million |
| 2020 | -153.45% | -151.44% | 0.39x | 2.58x | $-13.10 Million |
| 2021 | -12.67% | -49.71% | 0.19x | 1.36x | $-19.52 Million |
| 2022 | -50.26% | -143.14% | 0.20x | 1.79x | $-37.34 Million |
Industry Comparison
This section compares Item 9 Labs Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Item 9 Labs Corp (INLB) | $52.64 Million | 0.00% | 1.13x | $10.08K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |